ClinicalTrials.gg
Active, not recruitingNCT05964257Updated Sep 26, 2024

To Evaluate the Efficacy and Safety of LIZTOX in Subjects with Benign Masseteric Hypertrophy

A Phase 3 interventional study of Botulinum toxin type A and normal Saline in Benign Masseteric Hypertrophy, sponsored by Huons Biopharma. Active, not recruiting at 1 site in Korea, Republic of. Open to participants aged 19 Years and older. Per ClinicalTrials.gov, last updated 2024-09-26.

Sponsored by Huons Biopharma (part of Huons Global) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
188
Allocation
Randomized
Ages
19 Years and older
Sex
All
01

Study summary

A double-blind, randomized, placebo-controlled, multi-center, phase III study to evaluate the efficacy and safety of LIZTOX in subjects with benign Masseteric hypertrophy

02

Conditions studied

  • Benign Masseteric Hypertrophy

Keywords

  • BMH
03

In context

Lead sponsor

Huons Biopharma is the lead sponsor of 3 studies on the registry; 2 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
19 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female subject over 19 years of age and written is obtained.
  • Subject who has bilaterally symmetrical of masseter at visual and palpable assessment.
  • Subject who average masseter muscle thickness of at least 14mm on each side in males and 12mm in females at maximum clenching by ultrasonography.
  • Subject who has a masseter muscle hypertrophy scale of 4(marked) or more as determined by investigator.
  • Subject who fully understands this clinical trial and voluntarily writes ICF in the clinical trial.

Exclusion criteria

Exclusion Criteria:

  • Subject who had previously received botulinum toxin within 12 weeks prior to the study entry.
  • Subject who got any facial aesthetic procedure (e.g. surgery, laser, thread treatment etc.) in masseter muscle area within 48 weeks prior to the study entry.
  • Subject who has a disease(e.g. Temporo mandibular joint disorder, etc.)
  • Subject who were diagnosed Myasthenia gravis, Lambert-Eaton syndrome, amyotrophic lateral sclerosis, or any other condition that might influence with neuromuscular function.
  • Subject who had taken medication(e.g. muscle relaxant, polypeptide antibiotics, aminoglycoside antibiotics, etc.) within 4 weeks prior to the study entry.
  • Subject who are hypersensitive to drug components (botulinum toxin, serum albumin, etc.)
  • Subject who are pregnant or lactating or planing pregnancy or disagreed to avoid pregnancy during study period.
  • Subject who participate other clinical trials within 4 weeks prior to the study entry.
  • Subject who are not eligible for this study at the discretion of the investigator.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
188 participants (actual)

Study arms

  • Experimental
    HU-014

    Drug: Botulinum toxin type A

  • Placebo comparator
    Placebo

    Drug: normal Saline

Interventions

  • Botulinum toxin type A(HU-014) will be administered intramuscularly to the bilateral masseter muscles on Visit 2.

  • Drugnormal Saline

    Normal Saline will be administered intramuscularly to the bilateral masseter muscles on Visit 2.

06

What researchers measure

Primary outcomes

  1. Average change from baseline in masseter muscle thickness on both sides at maximum clenching

    The thickness of the masseter muscle is measured using ultrasonography, and the average value is obtained from three measurements.

    Time frame: 12weeks

Secondary outcomes

  1. Average change from baseline in masseter muscle thickness on both sides at maximum clenching

    The thickness of the masseter muscle is measured using ultrasonography, and the average value is obtained from three measurements.

    Time frame: 4, 8, 16, 20, 24weeks

  2. Average change from baseline in masseter muscle thickness on both sides at rest

    The thickness of the masseter muscle is measured using ultrasonography, and the average value is obtained from three measurements.

    Time frame: 4, 8, 12, 16, 20, 24weeks

  3. Average rate change from baseline in masseter muscle thickness on both sides at maximum clenching

    The thickness of the masseter muscle is measured using ultrasonography, and the average value is obtained from three measurements.

    Time frame: 4, 8, 12, 16, 20, 24weeks

  4. Average rate change from baseline in masseter muscle thickness on both sides at rest

    The thickness of the masseter muscle is measured using ultrasonography, and the average value is obtained from three measurements.

    Time frame: 4, 8, 12, 16, 20, 24weeks

  5. Change from baseline in the lower facial volume at maximum clenching and at rest using Morpheus 3D imaging

    When measuring, the volume of the lower face was measured twice and the average value was used.

    Time frame: 4, 8, 12, 16, 20, 24weeks

  6. Rate of change from baseline in the lower facial volume at maximum clenching and at rest using Morpheus 3D imaging

    When measuring, the volume of the lower face was measured twice and the average value was used.

    Time frame: 4, 8, 12, 16, 20, 24weeks

  7. The proportion of subjects who reported an overall improvement of more than 50% at maximum clenching and at rest.

    Overall improvement criteria: +4 (100% complete improvement) \~ -4 (100% very marked worsening)

    Time frame: 4, 8, 12, 16, 20, 24weeks

  8. The proportion of subjects who rated overall satisfaction as 'satisfied' at maximum clenching and at rest

    Overall satisfaction criteria: grade 1 (very dissatisfied) \~ grade 7 (very satisfied), Grade 6 or higher (satisfied, very satisfied) is evaluated as satisfied.

    Time frame: 4, 8, 12, 16, 20, 24weeks

  9. The proportion of subjects with a masseter muscle hypertrophy scale (MMHS) ≤3

    MMHS Evaluation criteria: The facial contour and the condition of the bilateral masseter muscles are assessed on a scale from grade 1 (minimal) to grade 5 (very marked).

    Time frame: 4, 8, 12, 16, 20, 24weeks

07

Study locations

1 site
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jul 2023 to primary completion in Mar 2024, 7 months.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 18, 2023
First posted
Jul 27, 2023
StartActual
Jul 25, 2023
Primary completionActual
Mar 7, 2024
CompletionEst.
May 30, 2025
Last update
Sep 26, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 26, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT05964257
Lead sponsor
Huons Biopharma
Responsible party
Sponsor
First posted
Jul 27, 2023
Start date
Jul 25, 2023
Primary completion
Mar 7, 2024
Completion
May 30, 2025 (estimated)
Last update
Sep 26, 2024

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Sep 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Botulinum toxin type A

Start the discussion